CLASS II Drug recall · Reported 26 Jun 2019 · FDA Enforcement Report

Anastrozole Tablets, 1 mg recalled by Zydus Pharmaceuticals USA

Zydus Pharmaceuticals USA is recalling Anastrozole Tablets, 1 mg, distributed nationwide in the US. The recall was initiated on 6 May 2019 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot: M706674, M706676, M707685 EXP Jun-19; M711219, M711220, M711221, M711222, M711269, EXP Sep-19; M801027, EXP Dec-19; M801028, M801029, M801030, EXP Jan-20; M802206, EXP Feb-20, M805195, M805196, M805197, EXP Mar-20; M805199, M805202, M805944, M805945, M805948, M805951, M805953, M805956, M805957, M805958, M805959 Apr-20; M812457, EXP Jul-20, M812458, M812459, M813912, M813913, M813914, M813915, M813916, EXP Aug-20; M815768, M815769, M818274, EXP Oct-20; M818119, M818120, M818121, M818635, EXP Nov-20; M819270, M819861, M819862, EXP Dec-20; M900921, M900922, M900923, M900924, M900925, EXP Jan-21; M902634, M902635, EXP Feb-21.
NDC68382-209
Quantity recalled1,425,264 30-count bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1440-2019
FDA event ID
82827
Recalling firm
Zydus Pharmaceuticals USA, Pennington, NJ
Manufacturer
Zydus Pharmaceuticals USA Inc.
Classification
Class II
Status
Terminated
Recall initiated
6 May 2019
FDA classified
1 Jul 2019
Reported
26 Jun 2019
Type
Voluntary: Firm initiated
Customers notified by
Letter

Timeline

6 May 2019Recall initiated by company
26 Jun 2019Published in enforcement report+51 days
1 Jul 2019Classified by FDA+5 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

Product as listed by the FDA

ANASTROZOLE Tablets, 1 mg, Rx Only, 30-count bottle, Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India. Distributed by: Zydus Pharmaceuticals (USA) Inc. Pennington, NJ 08534 NDC 68382-209-06

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Why was it recalled?

CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

Which lots are affected?

Lot: M706674, M706676, M707685 EXP Jun-19; M711219, M711220, M711221, M711222, M711269, EXP Sep-19; M801027, EXP Dec-19; M801028, M801029, M801030, EXP Jan-20; M802206, EXP Feb-20, M805195, M805196, M805197, EXP Mar-20; M805199, M805202, M805944, M805945, M805948, M805951, M805953, M805956, M805957, M805958, M805959 Apr-20; M812457, EXP Jul-20, M812458, M812459, M813912, M813913, M813914, M813915, M813916, EXP Aug-20; M815768, M815769, M818274, EXP Oct-20; M818119, M818120, M818121, M818635, EXP Nov-20; M819270, M819861, M819862, EXP Dec-20; M900921, M900922, M900923, M900924, M900925, EXP Jan-21; M902634, M902635, EXP Feb-21.

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

13 other products · FDA event 82827

This product is part of a recall event; the main page for the event is MethylPREDNISolone Tablets, USP, 4 mg recalled.

ReportedClassRecallCompanyReasonWhere
CLASS IIMethylPREDNISolone Tablets, USP, 4 mg recalledMethylprednisoloneZydus Pharmaceuticals USAManufacturing (CGMP) DeviationsNationwide
CLASS IIPramipexole Dihydrochloride Tablets 0.5 mg recalledZydus Pharmaceuticals USAManufacturing (CGMP) DeviationsNationwide
CLASS IIAnastrozole Tablets, USP, 1 mg recalled by Zydus Pharmaceuticals USAAnastrozoleZydus Pharmaceuticals USAManufacturing (CGMP) DeviationsNationwide
CLASS IIMethylPREDNISolone Tablets, USP 8 mg recalledMethylprednisoloneZydus Pharmaceuticals USAManufacturing (CGMP) DeviationsNationwide
CLASS IIMethylPREDNISolone Tablets, USP 16 mg recalledMethylprednisoloneZydus Pharmaceuticals USAManufacturing (CGMP) DeviationsNationwide
CLASS IIPramipexole Dihydrochoride Tablets 0.25 mg recalledZydus Pharmaceuticals USAManufacturing (CGMP) DeviationsNationwide
CLASS IIMethylPREDNISolone Tablets, USP dosepack recalledMethylprednisoloneZydus Pharmaceuticals USAManufacturing (CGMP) DeviationsNationwide
CLASS IIPramipexole DihydrochlorideTablets 0.125 mg recalledZydus Pharmaceuticals USAManufacturing (CGMP) DeviationsNationwide
CLASS IIPramipexole Dihydrochloride Tablets 1.5 mg recalledZydus Pharmaceuticals USAManufacturing (CGMP) DeviationsNationwide
CLASS IIPramipexole Dihydrochloride Tablets 0.125 mg recalledZydus Pharmaceuticals USAManufacturing (CGMP) DeviationsNationwide
CLASS IIPramipexole Dihydrochloride Tablets 0.25 mg recalledZydus Pharmaceuticals USAManufacturing (CGMP) DeviationsNationwide
CLASS IIMethylPREDNISolone Tablets, USP 32 mg recalledMethylprednisoloneZydus Pharmaceuticals USAManufacturing (CGMP) DeviationsNationwide
CLASS IIPramipexole Dihydrochloride Tablets 1 mg recalledZydus Pharmaceuticals USAManufacturing (CGMP) DeviationsNationwide

More recalls from Zydus Pharmaceuticals USA

All 41

Other Anastrozole recalls

All 6